Integrating Sequential Immunotherapy into Lung Cancer Treatment Plans
June 24, 2022
1 minute watch
Disclosures: Marmarelis reports holding shares and other interests in Bluebird Bio, Gilead Sciences, Johnson & Johnson, Merck, Pfizer and Portola Pharmaceuticals; receive honoraria from AstraZeneca, Blueprint Medicines, Health Advances, Janssen Oncology, Novocure, Takeda and Targeted Oncology; act as a consultant or advisor for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb/Celgene and Ikena Oncology; receive research funding for the Marmarelis institution from AstraZeneca, Lilly and Trizell; receive travel, accommodation and expenses from Boehringer Ingelheim and Novocure; and have another relationship with Novartis.
In this video, Melina Marmarelis, MD, highlights results from an unpaired Lung-MAP substudy presented at the ASCO Annual Meeting.
“The idea of sequential immunotherapy is something we’re all grappling with in this era of multiple different immunotherapies being approved in different lines,” said Marmarelis, an assistant professor of medicine at the University of Pennsylvania.
- Reckamp KL, et al. Overall survival from a randomized phase II study of ramucirumab plus pembrolizumab versus standard therapy for advanced non-small cell lung cancer previously treated with immunotherapy: unmatched Lung-MAP substudy S1800A. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.